報價延遲最少15分鐘:2025/06/26 19:56 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.6553 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.25/-0.26
|
|
企業價值
113.65M
|
| 資產負債 |
|
每股賬面淨值
0.14
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
16.89M
|
|
每股收益
0.10
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/26 19:56 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions. |